SGLT2 Inhibitors Reduced Rejection After Heart Transplant Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Reduced Rejection After Heart Transplant
SGLT2 Inhibitors Linked to Lower CKD Risk Before Kidney Disease Tags Coronary artery disease SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Linked to Lower CKD Risk Before Kidney Disease
Triple FDC Improved HbA1c More Than Dual Therapies in T2DM Tags hBA1c Sulphonylureas Biguanide α-Glucosidase inhibitors Read more about Triple FDC Improved HbA1c More Than Dual Therapies in T2DM
SGLT2i Use Shows Lower Stroke Risk in T2D With Retinopathy Tags Stroke hBA1c SGLT-2 Inhibitor Read more about SGLT2i Use Shows Lower Stroke Risk in T2D With Retinopathy
SGLT2i Linked to Lower Risk of ESKD in Nephrotic-Range Proteinuria Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about SGLT2i Linked to Lower Risk of ESKD in Nephrotic-Range Proteinuria
GLP-1RAs and SGLT2i Show Favorable Liver Outcome Profiles in T2DM Tags Sulphonylureas GLP-1 agonists DPP-4 inhibitors Thiazolidinediones Read more about GLP-1RAs and SGLT2i Show Favorable Liver Outcome Profiles in T2DM
Decision Support Tool Increases SGLT2i, GLP-1RA Use in T2DM Care Tags hBA1c GLP-1 agonists SGLT-2 Inhibitor Read more about Decision Support Tool Increases SGLT2i, GLP-1RA Use in T2DM Care
SGLT2 Inhibitors Linked to Higher DKA Risk at Elevated HbA1c Tags Diabetic ketoacidosis hBA1c SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Linked to Higher DKA Risk at Elevated HbA1c
Empagliflozin or Dapagliflozin for Cardiorenal Outcomes in T2DM? Tags Myocardial infarction Stroke SGLT-2 Inhibitor Read more about Empagliflozin or Dapagliflozin for Cardiorenal Outcomes in T2DM?
Do SGLT2i and DPP-4i Differ in Hematologic Malignancy Risk? Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about Do SGLT2i and DPP-4i Differ in Hematologic Malignancy Risk?